Compare LBRX & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LBRX | DGICB |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.2M | 562.0M |
| IPO Year | 2025 | N/A |
| Metric | LBRX | DGICB |
|---|---|---|
| Price | $22.65 | $15.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | ★ 239.5K | 2.1K |
| Earning Date | 02-15-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 4.24% |
| EPS Growth | N/A | ★ 219.91 |
| EPS | N/A | ★ 2.38 |
| Revenue | N/A | ★ $987,826,105.00 |
| Revenue This Year | N/A | $2.26 |
| Revenue Next Year | N/A | $3.46 |
| P/E Ratio | ★ N/A | $8.06 |
| Revenue Growth | N/A | ★ 0.89 |
| 52 Week Low | $13.36 | $13.19 |
| 52 Week High | $24.46 | $20.46 |
| Indicator | LBRX | DGICB |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 42.25 |
| Support Level | $21.82 | $15.26 |
| Resistance Level | $24.46 | $16.43 |
| Average True Range (ATR) | 1.84 | 0.36 |
| MACD | 0.08 | -0.25 |
| Stochastic Oscillator | 53.25 | 12.21 |
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.